| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2385 |
| Trial ID | NCT04436029 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | DesCAR-Tes-11 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy |
| Year | 2020 |
| Country | United States |
| Company sponsor | Cartesian Therapeutics |
| Other ID(s) | DC 11B |
| Cohort 1 | |||||||
|
|||||||